Incomplete Double-Stranded circRNA for Early SLE Diagnosis and Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current markers for systemic lupus erythematosus (SLE) are inadequate for early diagnosis, and there is a lack of effective treatments due to unclear pathogenesis.

Innovation Solution

Utilization of circRNAs with incomplete double-stranded structures of 16 bp-33 bp in length, or their promoting agents, for the development of medicaments to treat SLE, including methods for overexpression and combination therapies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If existing biochemical and immunological markers are used for diagnosis, then diagnosis can be performed, but early diagnosis of organ involvement cannot be achieved

Engineering Contradiction:

Improvediagnosis timingVSAvoidorgan involvement detection

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent uses circRNA molecules as diagnostic markers that copy or reflect the early pathological changes in SLE. By detecting circRNA expression patterns, the method captures early disease signals before traditional biochemical markers show changes, enabling earlier diagnosis of organ involvement.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent detects changes in circRNA expression levels and patterns as diagnostic parameters. By monitoring these molecular parameter changes in blood or tissue samples, the method can identify early organ involvement in SLE patients before conventional markers become abnormal.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional treatment methods are used, then current SLE management can be maintained, but fundamental prevention and treatment enhancement cannot be achieved

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidpathogenesis coverage

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and targets specific molecular pathways involved in SLE pathogenesis by using circRNA-based diagnostic information to guide treatment. This allows for more precise intervention in the underlying disease mechanisms rather than general symptom management.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

By enabling early diagnosis through circRNA detection, the patent allows for preliminary treatment intervention before significant organ damage occurs. This preliminary action can prevent or delay disease progression, fundamentally enhancing SLE management.

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If circRNA with incomplete double-stranded structure is used as therapeutic agent, then new treatment mechanism is provided, but treatment complexity increases

Engineering Contradiction:

Improvetreatment mechanismVSAvoidtreatment protocol

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The circRNA with incomplete double-stranded structure acts as a molecular intermediary that mediates therapeutic effects in SLE. This unique structural circRNA can interact with specific cellular targets to modulate immune responses, providing a novel treatment mechanism while the patent works to simplify delivery and administration protocols.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12383574B2Application of circular RNA in preparing drug for treating systemic lupus erythematosus

Publication Date: 2025.08.12 CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

AI summary

The present invention provides use of a circular RNA with an incomplete double-stranded structure of 16 bp-33 bp in length and/or a promoting agent of the circular RNA with an incomplete double-stranded structure of 16 bp-33 bp in length in preparation of a medicament for treating systemic lupus erythematosus.